These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 12897205)
1. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. Huang Y; Haraguchi M; Lawrence DA; Border WA; Yu L; Noble NA J Clin Invest; 2003 Aug; 112(3):379-88. PubMed ID: 12897205 [TBL] [Abstract][Full Text] [Related]
2. Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Huang Y; Border WA; Lawrence DA; Noble NA Kidney Int; 2006 Aug; 70(3):515-22. PubMed ID: 16788698 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. Huang Y; Border WA; Lawrence DA; Noble NA Am J Physiol Renal Physiol; 2009 Oct; 297(4):F1045-54. PubMed ID: 19625379 [TBL] [Abstract][Full Text] [Related]
4. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Haraguchi M; Border WA; Huang Y; Noble NA Kidney Int; 2001 Jun; 59(6):2146-55. PubMed ID: 11380816 [TBL] [Abstract][Full Text] [Related]
5. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Tomooka S; Border WA; Marshall BC; Noble NA Kidney Int; 1992 Dec; 42(6):1462-9. PubMed ID: 1474781 [TBL] [Abstract][Full Text] [Related]
6. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. Peters H; Daig U; Martini S; Rückert M; Schäper F; Liefeldt L; Krämer S; Neumayer HH Kidney Int; 2003 Aug; 64(2):509-18. PubMed ID: 12846746 [TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Lee EA; Seo JY; Jiang Z; Yu MR; Kwon MK; Ha H; Lee HB Kidney Int; 2005 May; 67(5):1762-71. PubMed ID: 15840023 [TBL] [Abstract][Full Text] [Related]
9. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. Huang Y; Border WA; Yu L; Zhang J; Lawrence DA; Noble NA J Am Soc Nephrol; 2008 Feb; 19(2):329-38. PubMed ID: 18216319 [TBL] [Abstract][Full Text] [Related]
10. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Zhang J; Noble NA; Border WA; Huang Y Am J Physiol Renal Physiol; 2010 Mar; 298(3):F579-88. PubMed ID: 20032116 [TBL] [Abstract][Full Text] [Related]
11. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. Hertig A; Berrou J; Allory Y; Breton L; Commo F; Costa De Beauregard MA; Carmeliet P; Rondeau E FASEB J; 2003 Oct; 17(13):1904-6. PubMed ID: 12897066 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Peters H; Border WA; Noble NA Kidney Int; 2000 Apr; 57(4):1493-501. PubMed ID: 10760085 [TBL] [Abstract][Full Text] [Related]
13. Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Ma LJ; Jha S; Ling H; Pozzi A; Ledbetter S; Fogo AB Kidney Int; 2004 Jan; 65(1):106-15. PubMed ID: 14675041 [TBL] [Abstract][Full Text] [Related]
14. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300 [TBL] [Abstract][Full Text] [Related]
15. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Peters H; Border WA; Noble NA Kidney Int; 2000 Mar; 57(3):992-1001. PubMed ID: 10720952 [TBL] [Abstract][Full Text] [Related]
16. A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes. Zhang J; Gu C; Lawrence DA; Cheung AK; Huang Y Exp Physiol; 2014 May; 99(5):802-15. PubMed ID: 24443353 [TBL] [Abstract][Full Text] [Related]
17. Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis. Hartner A; Hilgers KF; Bitzer M; Veelken R; Schöcklmann HO J Mol Med (Berl); 2003 Jan; 81(1):32-42. PubMed ID: 12545247 [TBL] [Abstract][Full Text] [Related]
19. Effects of transforming growth factor-beta 1 and phorbol ester on PAI-1 and PA genes in human lung cells. Jakowlew SB; Mariano JM; You L Growth Factors; 1997; 14(2-3):177-97. PubMed ID: 9255608 [TBL] [Abstract][Full Text] [Related]